Sequential abnormalities in type 1 diabetic encephalopathy and the effects of C-peptide

Review of Diabetic Studies

Volumn 6, Issue 3, 2009, Pages 211-222

  Sima, Anders A F ^a   Zhang, Weixian ^a   Muzik, Otto ^a   Kreipke, Christian W ^a   Rafols, José A ^a   Hoffman, William H ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

BB Wor rat; C peptide; Cerebral atrophy; Encephalopathy; Gray matter density; Hippocampus; Hyperglycemia; Inflammation; Intracerebral insulin signaling; Neuronal loss; Synaptic connectivity; Type 1 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C PEPTIDE; INSULIN; NEUROTROPHIC FACTOR;

APOPTOSIS; BEHAVIOR DISORDER; BRAIN ATROPHY; BRAIN DISEASE; CELL LOSS; COGNITIVE DEFECT; DIABETIC ENCEPHALOPATHY; GLUCOSE METABOLISM; GRAY MATTER; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NERVE CELL DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; REVIEW; SUBSTITUTION THERAPY; SYNAPTOGENESIS; WHITE MATTER;

EID: 76149120100     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2009.6.211     Document Type: Review

References (73)

1. Sima AA, Kamiya H, Li ZG. Insulin, C-peptide hyperglycemia and central nervous system complications in diabetes. Europ J Pharmacol 2004. 490:187-197.
2. Biessels GJ, Deary TJ, Ryan CM. Cognition and diabetes: a lifespan perspective. Lancet Neurol 2008. 7:184-190.
3. Biessels GJ. Diabetic encephalopathy. In: Veves A, Malik RA (eds). Diabetic Neuropathy - Clinical Management. Humana Press, Totowa, NJ. 2007, p. 187-205.
4. Sima AA. Pathobiology of diabetic encephalopathy. In: Biessels GJ, Luchsinger JA (eds). Humana Press, Totowa, NJ, 2009, p. 405-427.
5. Zhang W, Sima AA. The role glucose, cholesterol and insulin have in amyloidogenesis in human neuroblastoma cells. Proc XIX in Meeting of Neurodiab, Toronto, Canada, p. 21, 2009 (Abstract).
6. Ott A, Stolk RP, van Harskamp F, Pos HA, Hofman A, Breteler MM. Diabetes mellitus and risk of dementia: the Rotterdam study. Neurology 1999. 58:1937-1941.
7. Arvanitakis Z, Wilson RS, Bievas JL, Evans DA, Bennett DA. Alzheimer's disease and decline in cognitive function. Arch Neurol 2004. 61:661-666.
8. Peila R, Rodriquez BL, Lanner LJ. Type 2 diabetes, APOE gene and risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002. 51:1256-1262.
9. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Inamoto H, Nakayama K, Ohmori S, Nomiyama K, Kawano H, Ueda K. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population. The Hisayama Study. Neurology 1995. 445:1161-1168.
10. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmere E, O'Brien PC, Palumbo PJ. The risk of dementia among persons with diabetes mellitus: a population based cohort study. Ann NY Acad Sci 1997. 26:422-427.
11. Sima AA, Li ZG. Diabetes and Alzheimer's disease - is there a connection? Rev Diabet Stud 2007. 4:161-168.
12. Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007. 56:1817-1824.
13. Desrocher M, Rovet J. Neurocognitive correlates of type 1 diabetes mellitus in childhood. Child Neuropsychol 2004. 10:36-52.
14. Ryan C, Vega A, Drash A. Cognitive deficits in adolescents who developed diabetes early in life. Pediatrics 1985. 75:921-927.
15. Schoenle EJ, Schoenle D, Molinari L, Largo RH. Impaired intellectual development in children with type 1 diabetes: association with HbA(1c), age at diagnosis and sex. Diabetologia 2002. 45:108-114.
16. Northam EA, Anderson PJ, Jacobs R, Hughes M, Warne GL, Werther GA. Neuropsychological profiles of children with type 1 diabetes 6 years after disease onset. Diabetes Care 2001. 24:1541-1546.
17. Dahlquist G, Kallen B. School performance in children with type 1 diabetes - a population-based register study. Diabetologia 2007. 50:957-964.
18. Northam EA, Rankins D, Lin A, Wellard RM, Pell GS, Finch SJ, Werther GA, Cameron FJ. Central nervous system function in youth with type 1 diabetes 12 years after disease onset. Diabetes Care 2009. 32:445-450.
19. Ryan CM. Why is cognitive dysfunction associated with the development of diabetes early in life? The diathesis hypothesis. Pediatr Diabetes 2006. 7:289-297.
20. Fox MA, Chen RS, Holmes CS. Gender differences in memory and learning in children with insulin-dependent diabetes mellitus (IDDM) over a 4-year follow-up interval. J Pediatr Psychol 2003. 28:569-578.
21. Kramer L, Fasching P, Madl C, Schneider B, Damjancic P, Waldhäusl W, Irsigler K, Grimm G. Previous episodes of hypoglycemic coma are not associated with permanent cognitive brain dysfunction in IDDM patients on intensive insulin treatment. Diabetes 1998. 47:1909-1914.
22. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007. 356:1842-1852.
23. Autin EJ, Deary IJ. Effects of repeated hypoglycemia on cognitive function: a psychometrically validated reanalysis of the diabetes control and complications trial data. Diabetes Care 1999. 22:1273-1277.
24. Heikkilä O, Lundbom N, Timonen M, Groop PH, Heikkinen S, Mäkimattila S. Hyperglycemia is associated with changes in the regional concentrations of glucose and myo-inositol within the brain. Diabetologia 2009. 52:534-540.
25. Ho MS, Weller NJ, Ives FJ, Carne CL, Murray K, Vanden Driesen RI, Nguyen TP, Robins PD, Buisara M, Davis EA, Jones TW. Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus. J Pediatr 2008. 153(3):385-390.
26. Musen G, Lyoo IK, Sparks CR, Weinger K, Hwang J, Ryan CM, Jimerson DC, Henneu J, Renshaw PF, Jacobson AM. Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes 2006. 55:326-333.
27. Hoffman WH, Artlett CM, Zhang W, Kreipke CW, Passmore GG, Rafols J, Sima AA. Receptor for advanced glycation end products and neuronal deficit in the fatal brain edema of diabetic ketoacidosis. Brain Research 2008. 1238:154-162.
28. van Duinkerkeu E, Klein M, Schoonenboom NS, Hoogma RP, Moll AC, Snock FJ, Stain CJ, Diamant M. Functional brain connectivity and neurocognitive functioning in patients with longstanding type 1 diabetes with and without microvascular complications. Diabetes 2009. 58:2335-2343.
29. Brismar T, Hyllenmark L, Ekberg K, Johansson BL. Loss of temporal lobe beta power in young adults with type 1 diabetes mellitus. Neuro Report 2002. 13:2469-2473.
30. Jakobsen J, Sidenius P, Gundersen HJ, Osterby R. Quantitative changes of cerebral neocortical structure in insulin treated long-term streptozotocin-induced diabetes in rats. Diabetes 1987. 36:597-601.
31. Biessels GJ, Kamal A, Ramakers GM, Urban IJ, Spruijt BM, Erkeleus DL, Gispen WH. Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes 1996. 45:1259-1266.
32. Biessels GJ, Kamal A, Urban IJ, Spruijt BM, Erkeleus DW, Gispen WH. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effect of insulin treatment. Brain Res 1998. 800:125-135.
33. Kamal A, Biessels GJ, Gispen WH, Ramakers GM. Synaptic transmission changes in the pyramidal cells of the hippocampus in streptozotocin-induced diabetes mellitus in rats. Brain Res 2006. 1073:276-280.
34. Toth C, Schmidt AM, Tuor UI, Francis G, Foniok T, Brusse V, Kaur J, Yan SF, Martinez JA, Barber PA, Buchan A, Zochodne DW. Diabetes, leucoencephalopathy and RAGE. Neurobiol Dis 2006. 23:445-461.
35. Francis GJ, Martinez JA, Lin WQ, Xu Kevin, Ayes A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey II WH, Toth C. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type 1 diabetic encephalopathy. Brain 2008. 131:3311-3334.
36. Sima AA, Li ZG. The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetes. Diabetes 2005. 54:1497-1505.
37. Mordes JP, Bortell R, Groen H, Guburski D, Rossini AA, Greiner DL. Autoimmune diabetes mellitus in the BBrat. In: Sima AA, Shafrir E (eds). Animal Models of Diabetes. Harwood Academic Publ., Amsterdam, 2001, p. 1-42.
38. Sima AA (ed). Chronic complications in diabetes. Animal Models of Diabetes. Harwood Academic Publ., Amsterdam, 2000.
39. Kamija H, Zhang W, Sima AA. The beneficial effects of C-peptide on diabetic polyneuropathy. Rev Diabet Stud 2009. This issue.
40. Sima AA, Yagihashi S. Central-peripheral distal axonopathy in the spontaneously diabetic BB- rat: Ultrastructural and morphometric findings. Diabetes Res Clin Prac 1986. 1(5):289-298.
41. Kamijo M, Cherian PV, Sima AA. The preventive effect of aldose reductase inhibition on diabetic optic neuropathy in the BB/W-rat. Diabetologia 1993. 36:893-898.
42. Crusio WE, Schwegler H. Learning spatial orientation tasks in the radial-maze and structural variation in the hippocampus in inbred mice. Behav Brain Funct 2005. 1(1):3.
43. Wiener SI, Paul CA, Eichenbaum H. Spatial and behavioral correlates to hippocampal neuronal activity. J Neurosci 1989. 9:2737-2763.
44. Kreipke CW, Morgan R, Kallakuri S, Rafols JA. Behavioral pre-conditioning enhances angiogenesis and cognitive outcome after brain trauma. Neurol Res 2007. 29:388-394.
45. Balakrishnan S, Mathew J, Paulose CS. Cholinergic and glutamergic receptor functional regulation in long-term, low dose somatotropine and insulin treatment to aging rats: rejuvenation of brain function. Mol Cell Endocrinol 2010. 314:23-30.
46. Corner JM, Franks KM, Titterness AK, Russel K, Merrill DA, Christie BR, Sejnowski TJ, Tuszynski MH. NGF is essential for hippocampal plasticity and learning. J Neurosci 2009. 35:10883-10889.
47. Moon E, Her Y, Lee JB, Park JH, Lee EH, Kim SH, Oh MS, Jang CG, Kim SY. The multi-herbal medicine Gongjin-dan enhances memory and learning tasks via NGF regulation. Neurosci Lett 2009. 466(3):114-119.
48. Seto D, Zheng WH, McNicoll A, Collier B, Quirion R, Kar S. Insulin-like growth factor-I inhibits endogenous acetylcholine release from rat hippocampal formation: possible involvement of GABA in mediating the effects. Neuroscience 2002. 115(2):603-612.
49. Kar S, Seto D, Dore S, Hanisch U, Quirion R. Insulinlike growth factors-1 and -II differentially regulate endogenenous acetylcholine release from the rat hippocampal formation. Proc Natl Acad Sci USA 1997. 94:14054-14059.
50. Madara JC, Levine ES. Presynaptic and postsynaptic NMDA receptors mediate distinct effects of brain-derived neurotrophic factor on synaptic transmission. J Neurophysiol 2008. 100:3175-3184.
51. Grunberger G, Qiang X, Li ZG, Mathews ST, Sbriessa D, Shisheva A, Sima AA. Molecular basis for the insulinomimetic effects of C-peptide. Diabetologia 2001. 44:1247-1257.
52. Sima AA, Zhang W, Kreipke CW, Rafols JA, Hoffman WH. Inflammation in diabetic encephalopathy is prevented by C-peptide. Rev Diabet Stud 2009. 6:37-42.
53. Ramasamy R, Vanucci SJ, Yau SD, Herold K, Yau SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration and inflammation. Glycobiology 2004. 15:16R-28R.
54. Li ZG, Zhang W, Sima AA. C-peptide enhances insulin-mediated cell growth and protection against high glucose induced apoptosis in SH-SY5Y cells. Diabetes Metab Res Rev 2003. 19:375-385.
55. Hayden MS, Shosh S. Signaling to NF-kappaB. Genes Dev 2004. 18:2195-2224.
56. Cifarelli V, Luppi P, Tse HM, He J, Piganelli J, Trucco M. Human proinsulin C-peptide reduces high-glucose induced proliferation and NF-kappaB activation in vascular smooth muscle cells. Atherosclerosis 2008. 301:248-257.
57. Grunberger G, Sima AA. The C-peptide signaling. Exp Diab Res 2004. 5:25-36.
58. Sima AA, Zhang W, Kreipke CW. Immune responses in diabetic encephalopathy and the effects of C-peptide. C-peptide Satellite Symposium, EASD, Vienna, Austria, 2009 (Abstract).
59. Morris R. Development of a water maze procedure for studying spatial learning in the rat. J Neurosci 1984. 11:47-60.
60. Kamal A, Biessels GJ, Duis SE, Grispen WH. Learning and hippocampal plasticity in streptozotocin-diabetic rats: interaction of diabetes and aging. Diabetologia 2000. 43:500-506.
61. Medvedev NI, Rodriquez-Arellano JJ, Popov VI, Davies HA, Tigaret CM, Schoepfer R, Stewart MG. The glutamate receptor 2 subunits controls post-synaptic density complexity and spine shape in the dentate gyrus. Eur J Neurosci 2008. 27:315-325.
62. Tanaka H, Grooms SY, Bennett MV, Zukin RS. The AMPAR subunit GLUR2: still front and center stage. Brain Res 2000. 886:190-207.
63. Isaac JT, Asky M, McBain CJ. The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. Neuron 2007. 54:859-871.
64. McCormack SG, Stornetta RL, Zhu JJ. Synaptic AMPA receptor exchange maintains bidirectional plasticity. Neuron 2006. 50:76-88.
65. Li ZG, Zhang W, Sima AA. The role of impaired insulin/IGF action in primary diabetic encephalopathy. Brain Res 2005. 1037:12-24.
66. Li ZG, Sima AA. C-peptide and central nervous system complications in diabetes. Exp Diab Res 2004. 5:79-90.
67. Donaldson HH. A comparison of the albino rat with respect to the growth of the brain and the spinal cord. J Comp Neurol 1903. 33:345-393.
68. Dobbing J, Sands J. Vulnerability of developing brain: IX The effect of nutritional growth retardation on the timing of brain growth spurt. Biol Neonate 1971. 19:363-378.
69. Winick M, Noble A. Quantitative changes in DNA, RNA and protein during prenatal and post natal growth in the rat. Develop Biol 1965. 12:451-466.
70. Ehehalt S, Blumenstock G, Willasch AM, Hub R, Ranke MB, Neu A, DIARY-Study Group Baden-Württemberg. Continuous rise in incidence of childhood type 1 diabetes in Germany. Diabet Med 2008. 25:755-757.
71. Harjutsalo V, Sjöberg L, Tuomiletho J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008. 371:1777-1782.
72. Kumar P, Krishna P, Reddy SC, Gurappa M, Aravind SR, Munichoodappa C. Incidence of type 1 diabetes mellitus and associated complications among children and young adults: results from Karnataka Diabetes Registry 1995-2008. J Int Med Assoc 2008. 106:708-711.
73. Sima AA, Kamiya H. Is C-peptide replacement the missing link for successful treatment of neurological complications in type 1 diabetes? Current Drug Targets 2008. 9:37-46.